Mitchell Garrison MD

Oncology•Wenatchee, WA

Wenatchee Valley Medical Center

Join to View Full Profile

820 N Chelan AveWenatchee, WA 98801
Phone+1 509-663-8711
Fax+1 509-664-3417

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1998 - 2001
Madigan Army Medical CenterResidency, Internal Medicine, 1995 - 1998
Boston University School of MedicineClass of 1995

Certifications & Licensure

WA State Medical License 2006 - 2027
TX State Medical License 2002 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
Completed
Phase 2
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
COMPLETED
PHASE3
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
COMPLETED
PHASE3
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
Completed
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Natalie Wuliji, Salene M W Jones, Ted A Gooley, Aaron T Gerds, Bruno C Medeiros
Blood. 2025-03-11
13 citations
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres
Blood. 2023-01-19
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds
Blood. 2021-08-05

Lectures

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018